Related Experiment Video
Updated: Jul 12, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic
Wen-Xin Wang1,2, Xiaoyan Li2, Xue-Yuan Jin2
1Peking University 302 Clinical Medical School, Beijing 100039, China.
Background And Aims:
To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B (CHB) patients previously treated with nucleot(s)ide analogs (NAs) followed by combined treatment with an NA and pegylated interferon alpha (PEG-IFNα).
Methods:
Ninety-nine patients with serum levels of HBsAg <3000 IU/mL and HBV DNA <20 IU/mL who received prior NA treatment were enrolled. Participants were administered either NA monotherapy (NA group) or combination therapy with PEG-IFNα (Add-on group). Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12- and 24-week intervals. The outcome of this study was a loss or >1 log10 IU/mL decline in serum HBsAg.
Results:
After 48 weeks of antiviral therapy, none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss. Baseline serum HBsAg and IP-10 levels were equivalent across both groups. The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels. Furthermore, a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group. Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group (p < 0.05).
Conclusion:
An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNα among patients with CHB treated with NAs.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction